|
1
|
Habermann TM, Weller EA, Morrison VA, et
al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab
in older patients with diffuse large B-cell lymphoma. J Clin Oncol.
24:3121–3127. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coiffier B, Lepage E, Briere J, et al:
CHOP chemotherapy plus rituximab compared with CHOP alone in
elderly patients with diffuse large-B-cell lymphoma. N Engl J Med.
346:235–242. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Feugier P, Van Hoof A, Sebban C, et al:
Long-term results of the R-CHOP study in the treatment of elderly
patients with diffuse large B-cell lymphoma: a study by the Groupe
d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 23:4117–4126.
2005.PubMed/NCBI
|
|
4
|
Pfreundschuh M, Schubert J, Ziepert M,
Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M,
Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann
R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass
B, Poeschel V, Schmitz N, Ruebe C, Feller AC and Loeffler M; German
High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus
eight cycles of bi-weekly CHOP-14 with or without rituximab in
elderly patients with aggressive CD20+ B-cell lymphomas: a
randomised controlled trial (RICOVER-60). Lancet Oncol. 9:105–116.
2008.
|
|
5
|
Pfreundschuh M, Trümper L, Osterborg A,
Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani
PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen
T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M,
Rashford M, Kuhnt E and Loeffler M; MabThera International Trial
Group. CHOP-like chemotherapy plus rituximab versus CHOP-like
chemotherapy alone in young patients with good prognosis diffuse
large-B-cell lymphoma: a randomised controlled trial by the
MabThera International Trial (MInT) Group. Lancet Oncol. 7:379–391.
2006. View Article : Google Scholar
|
|
6
|
Feugier P, Virion JM, Tilly H, et al:
Incidence and risk factors for central nervous system occurrence in
elderly patients with diffuse large-B-cell lymphoma: influence of
rituximab. Ann Oncol. 15:129–133. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Boehme V, Schmitz N, Zeynalova S, Loeffler
M and Pfreundschuh M: CNS events in elderly patients with
aggressive lymphoma treated with modern chemotherapy (CHOP-14) with
or without rituximab: an analysis of patients treated in the
RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma
study group (DSHNHL). Blood. 113:3896–3902. 2009. View Article : Google Scholar
|
|
8
|
Villa D, Connors JM, Shenkier TN, Gascoyne
RD, Sehn LH and Savage KJ: Incidence and risk factors for central
nervous system relapse in patients with diffuse large B-cell
lymphoma: the impact of the addition of rituximab to CHOP
chemotherapy. Ann Oncol. 21:1046–1052. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamamoto W, Tomita N, Watanabe R, et al:
Central nervous system involvement in diffuse large B-cell
lymphoma. Eur J Haematol. 85:6–10. 2010.PubMed/NCBI
|
|
10
|
Tai WM, Chung J, Tang PL, et al: Central
nervous system (CNS) relapse in diffuse large B cell lymphoma
(DLBCL): pre- and post-rituximab. Ann Hematol. 90:809–818. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shimazu Y, Notohara K and Ueda Y: Diffuse
large B-cell lymphoma with central nervous system relapse:
prognosis and risk factors according to retrospective analysis from
a single-center experience. Int J Hematol. 89:577–583. 2009.
View Article : Google Scholar
|
|
12
|
Rubenstein JL, Combs D, Rosenberg J, et
al: Rituximab therapy for CNS lymphomas: targeting the
leptomeningeal compartment. Blood. 101:466–468. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reff ME, Carner K, Chambers KS, et al:
Depletion of B cells in vivo by a chimeric mouse human monoclonal
antibody to CD20. Blood. 83:435–445. 1994.PubMed/NCBI
|
|
14
|
Pels H, Schulz H, Manzke O, Hom E, Thall A
and Engert A: Intraventricular and intravenous treatment of a
patient with refractory primary CNS lymphoma using rituximab. J
Neurooncol. 59:213–216. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pels H, Schulz H, Schlegel U and Engert A:
Treatment of CNS lymphoma with the anti-CD20 antibody rituximab:
experience with two cases and review of the literature. Onkologie.
26:351–354. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schulz H, Pels H, Schmidt-Wolf I, Zeelen
U, Germing U and Engert A: Intraventricular treatment of relapsed
central nervous system lymphoma with the anti-CD20 antibody
rituximab. Haematologica. 89:753–754. 2004.PubMed/NCBI
|
|
17
|
Antonini G, Cox MC, Montefusco E, et al:
Intrathecal anti-CD20 antibody: an effective and safe treatment for
leptomeningeal lymphoma. J Neurooncol. 81:197–199. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu CY, Teng HW, Lirng JF, Chiou TJ, Chen
PM and Hsiao LT: Sustained remission and long-term survival of
secondary central nervous system involvement by aggressive B-cell
lymphoma after combination treatment of systemic high-dose
chemotherapy. Leuk Lymphoma. 49:2018–2021. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rubenstein JL, Fridlyand J, Abrey L, et
al: Phase I study of intraventricular administration of rituximab
in patients with recurrent CNS and intraocular lymphoma. J Clin
Oncol. 25:1350–1356. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bernstein SH, Unger JM, Leblanc M,
Friedberg J, Miller TP and Fisher RI: Natural history of CNS
relapse in patients with aggressive non-Hodgkin’s lymphoma: a
20-year follow-up analysis of SWOG 8516 - the Southwest Oncology
Group. J Clin Oncol. 27:114–119. 2009.
|
|
21
|
Abramson JS, Hellmann M, Barnes JA, et al:
Intravenous methotrexate as central nervous system (CNS)
prophylaxis is associated with a low risk of CNS recurrence in
high-risk patients with diffuse large B-cell lymphoma. Cancer.
116:4283–4290. 2010. View Article : Google Scholar
|
